中國生物制藥公(gong)(gong)(gong)告(gao)稱(cheng)，基于目前(qian)市(shi)場(chang)狀況(kuang)及(ji)公(gong)(gong)(gong)司發(fa)展規劃(hua)的(de)考慮，公(gong)(gong)(gong)司已(yi)決定不再繼續進(jin)行(xing)建(jian)議(yi)境內發(fa)行(xing)。公(gong)(gong)(gong)司與上市(shi)輔導機構一(yi)致同意終止有關建(jian)議(yi)境內發(fa)行(xing)的(de)上市(shi)輔導協議(yi)及(ji)其項下所有輔導工(gong)作，并(bing)已(yi)向證監會(北京監管(guan)局)報(bao)告(gao)終止情況(kuang)。公(gong)(gong)(gong)司將綜(zong)合考慮市(shi)場(chang)狀況(kuang)和發(fa)展需(xu)要，規劃(hua)未來相關安排。(全(quan)球企業(ye)動(dong)態)